1 – 10 of 36
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer : A study protocol of ARIADNE
- Contribution to journal › Article
- 2024
-
Mark
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial
- Contribution to journal › Article
-
Mark
Longitudinal molecular profiling elucidates immunometabolism dynamics in breast cancer
- Contribution to journal › Article
- 2023
-
Mark
Risk-adjusted benchmarking of long-term overall survival in patients with HER2-positive early-stage Breast cancer : A Swedish retrospective cohort study
- Contribution to journal › Article
- 2021
-
Mark
Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study
- Contribution to journal › Article
-
Mark
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients with ERBB2-Positive Breast Cancer : A Phase 2 Randomized Clinical Trial
- Contribution to journal › Article
- 2020
-
Mark
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer : Results from the phase 3 PANTHER trial
- Contribution to journal › Article
-
Mark
MNK2 governs the macrophage antiinflammatory phenotype
(2020) In Proceedings of the National Academy of Sciences of the United States of America 117(44). p.27556-27565
- Contribution to journal › Article
- 2019
-
Mark
Impact of Epithelial-Stromal Interactions on Peritumoral Fibroblasts in Ductal Carcinoma in Situ
- Contribution to journal › Article
-
Mark
Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease
- Contribution to journal › Article
